| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0003 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0006 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.19 | 0.0007 |
| mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0007 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0009 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.17 | 0.002 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.002 |